Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

Comments on Novartis Menveo vaccine

May 7, 2008

Analysis of:Novartis Menveo® vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial | www.novartis.com

An encouraging development, however since the vaccine does not cover group B meningococcal disease, vigilance will be required among vaccinated individuals to insure that symptomatic individuals are not infected with group B meningococci. The human bactericidal antibody response is considered the more relevant measure of antibody protection (rather than geometric mean titer).

Page : 11 to 1 of 1

Request a News Analysis

Subscribe to Updates

By RSS